BackHalozyme Therapeutics Overview

Halozyme Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for HALO.

Quarterly EBIT

$184.52M
↑ 24.38% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

$871.50M
↑ 42.51% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin